Actuate Therapeutics Joins Russell 3000 and 2000 Indexes Amidst Cancer Treatment Breakthroughs

Chicago, Monday, 16 June 2025.
Actuate Therapeutics has been included in both the Russell 3000 and 2000 indexes as of June 16, 2025, highlighting its growth and innovative efforts in metastatic pancreatic cancer treatment.